Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025

Vinge has advised Eleda in connection with its acquisition of Rail Solutions Scandinavia AB, Gridtec AB, Quantity Surveying Konsult Stockholm AB, Voene AB, Vägservice centralen i Norden AB and Frästech AB.

Vinge has advised the leading infrastructure group Eleda in connection with its parallel acquisitions of Rail Solutions Scandinavia (railway maintenance), Gridtec (engineering consultancy in electric power), Quantity Surveying Konsult Stockholm (cost control and project management), Voene (traffic safety), Vägservice centralen i Norden and Frästech (road and bridge maintenance). The acquired businesses had a strong profitability with a combined turnover of approximately 200 MSEK in 2024.
June 04, 2025